MENU

GILD Stock Gilead Sciences (GILD, $92.8) entered a monthly bullish trend. Expect an Uptrend continuation

A.I.dvisor
at Tickeron.com
Loading...
GILD - Gilead Sciences
Bullish Trend Signal
Bullish Trend
Odds of UP Trend
Tickeron

Loading...

Price: $92.8
Daily change: +$0.75 (+0.81%)
Daily volume: 6M
Capitalization: $115.7B
Industry: Pharmaceuticals: Major
Gilead Sciences (GILD, $92.8) is predicted by A.I.dvisor to grow by to $96.51 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended up during the month, the odds of an Uptrend continuation are

GILD in +1.03% Uptrend, growing for three consecutive days on December 17, 2024

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GILD advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 17, 2024. You may want to consider a long position or call options on GILD as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 236 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GILD moved out of overbought territory on November 12, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on December 06, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.976) is normal, around the industry mean (5.632). P/E Ratio (16.196) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.451) is also within normal values, averaging (3.004). Dividend Yield (0.041) settles around the average of (0.164) among similar stocks. P/S Ratio (3.381) is also within normal values, averaging (3.643).

View a ticker or compare two or three
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutic products and treatments for life threatening diseases

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Lakeside Drive
Phone
+1 650 574-3000
Employees
18000
Web
https://www.gilead.com